image description

Tag: Lucin

Championing Patient Power in Lupus

January 24, 2024 Dr. Stacie Bell came to LRA’s clinical research affiliate Lupus Therapeutics (LT) one year ago to help fulfill the vision of an entire community united to triumph over a complex and confounding disease.  She joined determined to work with the researchers, clinicians, biopharmaceutical companies, and most importantly the people with lupus and […] Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, NY, June 2, 2023 — Lupus Research Alliance clinical research affiliate Lupus Therapeutics will collaborate with Novartis Pharmaceuticals Corporation to conduct  three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America. Read More

NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

August 31, 2022 We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food […] Read More

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] Read More

Tips on How Men Can Cope with Lupus from HSS Professional

October 7, 2021 In recognition of Hispanic Heritage Month, we are sharing a blog post from Latina professional Priscilla Toral, LCSW at Hospital for Special Surgery for managing as a male with lupus. The Hispanic/Latino community are among those at higher risk for lupus. Lupus is traditionally known as a woman’s disease, because it affects […] Read More

LRA is Unraveling Lupus Heterogeneity to Turn Complexity to Cure

July 22, 2021 Why is lupus so tough to treat? Why is it so difficult to test possible new treatments in a clinical trial? Why are so many people needed for a clinical trial to prove effectiveness? And how does LRA intend to Turn Lupus Complexity to Cure? The answers lie at the core of […] Read More

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] Read More